CryoPort Inc (CYRX)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013280)
◆英語タイトル:CryoPort Inc (CYRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013280
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:42
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥32,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥64,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥96,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Cryoport Inc (Cryoport) is a provider of cold chain logistics solutions for temperature-sensitive biological materials to the life science industries. It offers liquid nitrogen dry vapor shippers with advanced logistics management platform called Cryoportal, which provides credentials related to the shipment. It also offers SmartPak II condition monitoring system that provides information regarding the shipment including pressure, light, orientation, location, temperature, humidity and shock. Cryoport provides logistics consulting regarding all aspects including supply chain optimization from the manufacturer to patient, staff training, software installation and site assessment. It offers services to biopharmaceutical institutions including contract manufacturers, labs, diagnostics, clinical trial centers; academic and research institutions; in-vitro fertility (IVF) industry and animal health market. Cryoport is headquartered in Irvine, California, the US.

CryoPort Inc (CYRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CryoPort Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CryoPort Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CryoPort Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CryoPort Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
CryoPort Inc, Pharmaceuticals & Healthcare, Deal Details 9
Equity Offering 9
Cryoport Raises USD12.7 Million in Public Offering of Shares 9
CryoPort Raises USD6.8 Million in Public Offering of Units 11
CryoPort Completes Third Tranche Of Private Placement Of Units For US$0.4 Million 13
CryoPort Completes First Round Of Private Placement For US$4.43 Million 14
Debt Offering 15
CryoPort Completes Private Placement Of Debt Securities For US$0.3 Million 15
CryoPort Inc – Key Competitors 16
CryoPort Inc – Key Employees 17
CryoPort Inc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Strategy And Business Planning 19
Apr 11, 2016: Cryoport Announces Global Temperature Controlled Logistics Consulting Services 19
Jan 26, 2016: Cryoport Introduces Its Advanced Cryogenic Logistics Solutions for IVF to the Cambodia and Czech Republic Markets 21
Financial Announcements 22
Nov 02, 2017: Cryoport Revenue Up 52%; Driven by BioPharma 22
Aug 08, 2017: Cryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma 24
Mar 13, 2017: Cryoport Revenue Continues to Climb, Reporting 53% Growth for the Quarter Ended December 31, 2016 26
Nov 14, 2016: Cryoport Reports 38% Revenue Growth for the Second Quarter of Fiscal Year 2017 28
Aug 15, 2016: Cryoport Continues to Climb, Reporting 34% Revenue Growth for the First Quarter of Fiscal Year 2017 30
Jun 27, 2016: Cryoport Reports 50% Revenue Growth for Fiscal Year 2016 32
Feb 08, 2016: Cryoport Reports 50% Revenue Growth for the Third Quarter of Fiscal Year 2016 34
Government and Public Interest 35
Jun 07, 2017: Cryoport Expands Agreement with Sanaria to Support Grant Awards with U.S. National Institutes of Health and U.S. Army 35
Oct 25, 2016: Cryoport Supporting Over 100 Clinical Trials 36
Product News 37
Jun 20, 2016: Cryoport Launches Next Generation Condition Monitoring Technology 37
Other Significant Developments 38
Jan 17, 2017: Cryoport to Support ProMab Biotechnologies’ CAR-T Cell Preclinical Services 38
Sep 22, 2016: Cryoport and Database Integrations Launch Integrated Solution to Manage Patient and Manufacturer Schedules at Every Stage of the Clinical Trial Logistics Process 39
Aug 02, 2016: Cryoport to Support World-Leading Life Science Company’s Custom Development and Biologics Manufacturing Business 40
Jun 15, 2016: Cryoport Enters Bio-Storage Market 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
CryoPort Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
CryoPort Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
CryoPort Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CryoPort Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CryoPort Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CryoPort Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Cryoport Raises USD12.7 Million in Public Offering of Shares 9
CryoPort Raises USD6.8 Million in Public Offering of Units 11
CryoPort Completes Third Tranche Of Private Placement Of Units For US$0.4 Million 13
CryoPort Completes First Round Of Private Placement For US$4.43 Million 14
CryoPort Completes Private Placement Of Debt Securities For US$0.3 Million 15
CryoPort Inc, Key Competitors 16
CryoPort Inc, Key Employees 17
CryoPort Inc, Subsidiaries 18

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ CryoPort Inc (CYRX)-製薬・医療分野:企業M&A・提携分析(CryoPort Inc (CYRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆